[ad_1]
U.S. stocks are poised to rise on Monday ahead of a week of earnings and economic data releases, including quarterly reports from Tesla, Netflix, and .
Source link

[ad_1]
Newswise — SAN FRANCISCO — Two simple solutions could help prevent severe bleeding (postpartum hemorrhage) after cesarean delivery, suggests research presented at the ANESTHESIOLOGY® 2023 annual meeting. As the leading cause of maternal mortality in the U.S. at the time of birth, postpartum hemorrhage is more common after cesarean deliveries than vaginal births.
Both solutions help address uterine atony, which causes up to 80% of postpartum hemorrhage. Uterine atony is when, after delivery, the uterus remains soft and weak instead of contracting to compress the blood vessels that had been attached to the placenta. One solution involves infusing a medication to help the uterus contract after delivery. The other is an early warning system that prompts an assessment of how well the uterus is contracting after delivery to quickly alert the health care team when a woman is at risk for heavy bleeding and requires treatment.
“Bleeding during a cesarean delivery is a high-stakes, high-risk situation, and when it occurs, the obstetrics and anesthesia teams must work together to rapidly prevent and treat ongoing bleeding,” said James Xie, M.D., lead author of the early warning study and clinical assistant professor of anesthesiology, perioperative and pain medicine at Stanford University, California. “Studies have shown that rapid recognition and management are essential to improving outcomes.”
“The ultimate goal is to decrease maternal mortality and morbidity,” said Jessica Ansari, M.D., M.S., senior author for both studies and an obstetric anesthesiologist at Stanford University. “Recent estimates show a new mother dies of postpartum hemorrhage about every seven minutes, mostly in low-resource settings. If our findings can be confirmed in larger studies, it could transform the way we prevent and treat postpartum hemorrhage.”
Calcium chloride infusion
The researchers looked at using calcium chloride to help prevent bleeding in women with uterine atony because it is inexpensive, simple, safe and doesn’t require refrigeration like other treatments. Consequently, it can be used even in very low-resource settings, where women are much more likely to die from pregnancy-related bleeding. They found that calcium chloride reduced the amount of bleeding that patients experienced during their cesarean delivery by nearly a measuring cup (more than 200 mL).
The double-blind, randomized, controlled trial included 120 women who required a cesarean delivery after labor with an oxytocin infusion (which increases contraction of the uterus during labor), placing them at much higher risk of suffering from uterine atony and bleeding after the birth. Researchers randomly assigned 60 women to receive 1-gram infusions of calcium chloride and 60 women to receive a placebo. The infusion was administered slowly after the baby was delivered, and the study was blinded, meaning the patients and their doctors were unaware if they received calcium or the placebo. Of the women who received the placebo, 57% had postpartum hemorrhage and 15% required a blood transfusion, while 40% of those who received calcium chloride had postpartum hemorrhage and 8.3% required a blood transfusion.
The last Food and Drug Administration-approved drug to treat uterine atony was released in 1979.
“New treatments to treat uterine atony are desperately needed,” said Alla Yarmosh, M.D., lead author of the study and clinical assistant professor in anesthesiology at Stanford University. “This is the first time an infusion of calcium chloride has been studied as a possible treatment to help the uterus contract after cesarean delivery and decrease bleeding in those patients. If our findings are confirmed by larger studies, it would be an easy technique for institutions to implement since anesthesiologists run infusions during surgery regularly.”
Early warning system
For the early warning study, researchers created an alert that pops up on the anesthesiologist’s electronic health record (EHR) module two minutes after the baby is marked as delivered, asking for a uterine score from 1-10. The anesthesiologist prompts the obstetrician to assess the uterine tone (by manually feeling it) and provide the score, which the anesthesiologist records. Scores of 6 or lower mean the uterus is not contracting well and the woman is at higher risk for postpartum hemorrhage.
This real-time communication that a woman is at risk alerts the treatment team, which can then determine the best solution. Physicians can give the woman medications to help the uterus contract better or put stitches or balloons in the uterus to compress the vessels to prevent further bleeding, said Dr. Xie. They also can anticipate and prepare for hemorrhage, which can be addressed by giving the woman medications to stabilize blood clotting or ordering blood products to be ready for transfusion.
The study assessed more than 1,000 consecutive cesarean deliveries by 70 different obstetricians over eight months. The uterine tone score was assessed three times for each patient and was documented reliably; two minutes after delivery (recorded 87% of the time), seven minutes after delivery (recorded 97% of the time), and 12 minutes after delivery (recorded 98% of the time). At 12 minutes, 179 women (18%) had scores of 6 or lower, meaning they were at higher risk for severe bleeding. Of those with scores of 6 or lower, 77% experienced hemorrhage, 46% experienced major hemorrhage and 25% needed a blood transfusion.
“Our research shows that this simple scoring system is a very meaningful, easy way to ensure that if the uterus is contracting poorly and there is a risk of hemorrhage, it will be recognized by their health care team early,” said Dr. Xie. “In the future we can further refine models that predict when women are at high risk of bleeding around the time of delivery to help physicians be prepared to manage bleeding caused by poor uterine tone.”
The United States has the highest maternal mortality rate among high-income countries.
THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS
Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific professional society with more than 56,000 members organized to advance the medical practice of anesthesiology and secure its future. ASA is committed to ensuring anesthesiologists evaluate and supervise the medical care of all patients before, during and after surgery. ASA members also lead the care of critically ill patients in intensive care units, as well as treat pain in both acute and chronic settings.
For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about how anesthesiologists help ensure patient safety, visit asahq.org/madeforthismoment. Join the ANESTHESIOLOGY® 2023 social conversation today. Like ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES23.
[ad_2]
American Society of Anesthesiologists (ASA)
Source link

[ad_1]
Newswise — Biochemists from RUDN University described how to prevent cancer cells from becoming resistant to chemotherapy drugs. Having determined the resistance mechanism, biochemists selected a drug that can slow down it. The results were published in the International Journal of Molecular Sciences.
Chemotherapy remains the mainstay of cancer treatment in most cases. One of the most common anticancer drugs is the platinum-containing cisplatin. It is effective in the fight against sarcomas and other types of malignant tumors. The disadvantage of this treatment is the gradually emerging resistance of tumor cells to the antitumor drug. Biochemists from RUDN have described a method that allows one to “cancel” resistance to cisplatin in vitro on ovarian cancer cells.
“Platinum-based anticancer drugs, such as cisplatin, are established chemotherapeutic agents in the treatment of certain types of malignancies. However one of the main obstacles to effective chemotherapy is resistance to cisplatin. Drug resistance can develop through several mechanisms. Our goal was to understand these mechanisms and study possible ways to eliminate resistance,” said Elena Kalinina, Doctor of Biological Sciences, Professor of the Department of Biochemistry, RUDN University.
Previously, RUDN biochemists discovered that cisplatin resistance in ovarian cancer cells is affected by overexpression of several genes. The authors also showed that quercetin (a compound from the group of flavonoids) helps reduce this effect. Therefore, biochemists have suggested that treating cells with quercetin first and then with cisplatin can help avoid resistance. Biochemists tested this assumption on cancer cells of the SKOV-3/CDDP lines.
Preincubation of tumor cells with quercetin before exposure to cisplatin resulted in significantly improved outcomes. With 48 hours of preincubation at the optimal dose (60 micromoles), quercetin reduces the proportion of surviving cancer cells to approximately 25% if the action time of cisplatin is also 48 hours. Without prior exposure to quercetin, this proportion is about 80%.
“Our in vitro data show that quercetin sensitizes cisplatin-resistant cells. To confirm that, further studies are needed with other cell lines that are resistant not only to cisplatin but also to other anticancer drugs. Future experiments will be aimed at confirming the effect of preincubation with quercetin in vivo. This will allow us to evaluate its potential for eliminating resistance to cisplatin in tumor cells,” said Elena Kalinina, Doctor of Biological Sciences, Professor of the Department of Biochemistry, RUDN University.
[ad_2]
Russian Foundation for Basic Research
Source link

[ad_1]
Newswise — CAMBRIDGE, MA — The genome of the SARS-CoV-2 virus encodes 29 proteins, one of which is an ion channel called E. This channel, which transports protons and calcium ions, induces infected cells to launch an inflammatory response that damages tissues and contributes to the symptoms of Covid-19.
MIT chemists have now discovered the structure of the “open” state of this channel, which allows ions to flow through. This structure, combined with the “closed” state structure that was reported by the same lab in 2020, could help scientists figure out what triggers the channel to open and close. These structures could also guide researchers in developing antiviral drugs that block the channel and help prevent inflammation.
“The E channel is an antiviral drug target. If you can stop the channel from sending calcium into the cytoplasm, then you have a way to reduce the cytotoxic effects of the virus,” says Mei Hong, an MIT professor of chemistry and the senior author of the study.
MIT postdoc Joao Medeiros-Silva is the lead author of the study, which appears today in Science Advances. MIT postdocs Aurelio Dregni and Pu Duan and graduate student Noah Somberg are also authors of the paper.
Open and closed
Hong has extensive experience in studying the structures of proteins that are embedded in cell membranes, so when the Covid-19 pandemic began in 2020, she turned her attention to the coronavirus E channel.
When SARS-CoV-2 infects cells, the E channel embeds itself inside the membrane that surrounds a cellular organelle called the ER-Golgi intermediate compartment (ERGIC). The ERGIC interior has a high concentration of protons and calcium ions, which the E channel transports out of ERGIC and into the cell cytoplasm. That influx of protons and calcium leads to the formation of multiprotein complexes called inflammasomes, which induce inflammation.
To study membrane-embedded proteins such as ion channels, Hong has developed techniques that use nuclear magnetic resonance (NMR) spectroscopy to reveal the atomic-level structures of those proteins. In previous work, her lab used these techniques to discover the structure of an influenza protein known as the M2 proton channel, which, like the coronavirus E protein, consists of a bundle of several helical proteins.
Early in the pandemic, Hong’s lab used NMR to analyze the structure of the coronavirus E channel at neutral pH. The resulting structure, reported in 2020, consisted of five helices tightly bundled together in what appeared to be the closed state of the channel.
“By 2020, we had matured all the NMR technologies to solve the structure of this kind of alpha-helical bundles in the membrane, so we were able to solve the closed E structure in about six months,” Hong says.
Once they established the closed structure, the researchers set out to determine the structure of the open state of the channel. To induce the channel to take the open conformation, the researchers exposed it to a more acidic environment, along with higher calcium ion levels. They found that under these conditions, the top opening of the channel (the part that would extend into the ERGIC) became wider and coated with water molecules. That coating of water makes the channel more inviting for ions to enter.
That pore opening also contains amino acids with hydrophilic side chains that dangle from the channel and help to attract positively charged ions.
The researchers also found that while the closed channel has a very narrow opening at the top and a broader opening at the bottom, the open state is the opposite: broader at the top and narrower at the bottom. The opening at the bottom also contains hydrophilic amino acids that help draw ions through a narrow “hydrophobic gate” in the middle of the channel, allowing the ions to eventually exit into the cytoplasm.
Near the hydrophobic gate, the researchers also discovered a tight “belt,” which consists of three copies of phenylalanine, an amino acid with an aromatic side chain. Depending on how these phenylalanines are arranged, the side chains can either extend into the channel to block it or swing open to allow ions to pass through.
“We think the side chain conformation of these three regularly spaced phenylalanine residues plays an important role in regulating the closed and open state,” Hong says.
Viral targeting
Previous research has shown that when SARS-CoV-2 viruses are mutated so that they don’t produce the E channel, the viruses generate much less inflammation and cause less damage to host cells.
Working with collaborators at the University of California at San Francisco, Hong is now developing molecules that could bind to the E channel and prevent ions from traveling through it, in hopes of generating antiviral drugs that would reduce the inflammation produced by SARS-CoV-2.
Her lab is also planning to investigate how mutations in subsequent variants of SARS-CoV-2 might affect the structure and function of the E channel. In the Omicron variant, one of the hydrophilic, or polar, amino acids found in the pore opening is mutated to a hydrophobic amino acid called isoleucine.
“The E variant in Omicron is something we want to study next,” Hong says. “We can make a mutant and see how disruption of that polar network changes the structural and dynamical aspect of this protein.”
###
The research was funded by the National Institutes of Health and the MIT School of Science Sloan Fund.
[ad_2]
Massachusetts Institute of Technology (MIT)
Source link
[ad_1]
Newswise — University of Maryland School of Medicine (UMSOM) researchers conducted a statewide survey of all patients on breathing machines in hospitals and long-term care facilities and found that a significant percentage of them harbored two pathogens known to be life-threatening in those with compromised immune systems. One pathogen, Acinetobacter baumannii, was identified in nearly 31 percent of all patients on ventilators to assist with their breathing; Candida auris was identified in nearly 7 percent of patients on ventilators, according to the study which was published this week in the Journal of the American Medical Association.
They conducted the study with colleagues at the Maryland Department of Health and presented their findings at this week’s Infectious Disease Society of America annual meeting in Boston.
“We found patients in long-term care facilities, like skilled nursing homes, were more likely to be colonized with these pathogens than those getting treated in hospitals,” said study leader Anthony Harris, MD, MPH, Professor of Epidemiology & Public Health at UMSOM and infectious disease specialist at University of Maryland Medical Center. “We were the first in the nation to get a statewide survey of all ventilated patients, and I think it points to the stringency of the infection control programs in place in the state of Maryland and the excellent collaboration between the University of Maryland and the State Health Department.”
Both A. baumannii and C. auris have been highlighted by the federal Centers for Disease Control and Prevention (CDC) as emerging pathogens that present a global health threat. C. auris is a fungus that spreads within and among local healthcare facilities–usually in those hospitalized and on breathing machines (ventilators). Older people with weakened immune systems are particularly susceptible to this infection, which resists treatment with common anti-fungal medications. A. baumannii, a bacteria, also poses a threat to these same types of patients and has become very resistant through the years to treatment with most antibiotics.
To conduct the study, Dr. Harris and his colleagues obtained culture swabs from all 482 patients receiving mechanical ventilation in Maryland healthcare facilities between March and June of this year. All eligible healthcare facilities, 51 in total, participated in the survey. They identified A. baumannii from at least one patient in one-third of the acute care hospitals and from 94 percent of the long-term care facilities. They identified C. auris in nearly 5 percent of hospitalized patients and in 9 percent of patients in long-term care facilities.
“Testing positive, however, does not mean that patients have symptoms or active infections that are potentially life-threatening,” said study co-author J. Kristie Johnson, PhD, Professor of Pathology at UMSOM whose lab did the A. baumannii testing for the study. “But knowing which patients are colonized with these pathogens can help contain their spread to other patients.”
Over the course of 2022, state and local health departments around the country reported 2,377 clinical cases, according to the CDC, nearly five times the number infections in 2019, which was less than 500 cases. Maryland alone had 46 cases in 2022. While these infections don’t normally pose much of health risk to hospital workers, they pose a significant risk of death in patients with weakened immune systems. Often the infections can be spread from patient to patient by health care workers carrying the germs on their hands, equipment or clothing.
“There is a need for more health care facilities nationwide to be aware of the extent of the problem through surveillance testing,” Dr. Harris said. Certain measures can be implemented to help reduce spread of these pathogens including more stringent use of disposable gloves and gowns between patients and the use of chlorhexidine bathing of the critically ill to disinfect their skin.
“Emerging pathogens that are resistant to available therapeutics present a growing challenge in our country, especially with a projected increased growth in our aging population entering long term care facilities,” said UMSOM Dean Mark Gladwin, MD, who is also Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor at UMSOM. “Nearly half of patients who contract C. auris infections die within 90 days, according to the CDC, and this pathogen is now found in nearly 50 states. This is why it is critical for these surveillance studies to be conducted nationwide, not just in Maryland.”
UMSOM faculty members Lisa Pineles, MA, Lyndsay O’Hara, PhD, Leigh Smith, MD, and Indira French, MS, were co-authors on this study. The study was funded by a grant from the CDC (1U54CK000450-01).
About the University of Maryland School of Medicine
Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world — with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic, and clinically based care for nearly 2 million patients each year. The School of Medicine has more than $500 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2023, the UM School of Medicine is ranked #10 among the 92 public medical schools in the U.S., and in the top 16 percent (#32) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu
[ad_2]
University of Maryland School of Medicine
Source link

[ad_1]
Newswise — Johns Hopkins School of Nursing Professor Bonnielin Swenor, PhD, MPH, BS, also founder and director of the Johns Hopkins Disability Health Research Center, has been named the inaugural Endowed Professor of Disability Health and Justice.
“Dr. Bonnielin Swenor is an incredible researcher, scientist, and educator with an unrelenting drive to ensure that people with disabilities are able to thrive,” says JHSON Dean Sarah Szanton, PhD, RN, FAAN. “Her installation as an endowed chair formally acknowledges the impact her career has made, and our trust in all there is to come.”
“Dr. Swenor and the Center are committed to training the next generation of disability equity researchers, including researchers with disabilities,” says Jermaine Monk PhD, MSW, MS Mgmt, MA Th, MA, Associate Dean of Diversity, Equity, Inclusion, and Belonging. “That is so important to build into nursing education as we prepare the next generation of nurses.”
The chair was funded by the estates of Ms. Charlotte B. Lockner, School of Nursing alumna from the Class of 1955; Mr. Ralph S. O’Connor, University Trustee and Krieger School of Arts and Sciences alumnae from the class of 1951; and Antoinette Delruelle and Joshua L. Steiner, along with The Maryland E-Nnovation Initiative Fund Authority.
Today more than 27 percent of American adults have a disability, and yet people with disabilities still face many barriers to health, equity, and inclusion.
With that in mind, the Endowed Professorship of Disability Health and Justice was established to push scientific discovery and develop innovative, evidence-based strategies to foster inclusion of people with disabilities into the workforce.
Dr. Swenor founded and directs the Johns Hopkins Disability Health Research Center, which is home to experts across disciples who test and collaborate on data-driven approaches to reduce disability inequity. It officially moved to the School of Nursing in 2022 when Dr. Swenor joined the faculty. The professorship will fund Dr. Swenor and the Center to develop novel tools that inform policy and integrate artificial intelligence (AI) and other technologies into new disability health tools.
“I am honored to be the inaugural Endowed Professor of Disability Health and Justice,” says Dr. Swenor. “We aim to shift the paradigm from ‘living with a disability’ to ‘thriving with a disability’ and maximize the health, equity, and participation of people with disabilities.”
Through this endowed chair, Dr. Swenor and the Johns Hopkins Disability Health Research Center will have significant impact on our ability to build up activism and visibility in the disability community.
***
Located in Baltimore, the Johns Hopkins School of Nursing is a globally-recognized leader in nursing education, research, and practice. In U.S. News & World Report rankings, the school is No. 1 nationally for its DNP program and No. 2 for its master’s. In addition, JHSON is ranked as the No. 3 nursing school in the world by QS World University. The school is a five-time recipient of the INSIGHT Into Diversity Health Professions Higher Education Excellence in Diversity (HEED) Award and a four-time Best School for Men in Nursing award recipient. For more information, visit www.nursing.jhu.edu.
[ad_2]
Johns Hopkins School of Nursing
Source link

[ad_1]
Newswise — In 2023, life expectancy in Korea will be 83.6 years, the third highest among OECD countries, and it is steadily increasing every year. As the proportion of the elderly population increases, the social cost of treating various geriatric diseases is also increasing rapidly, and there is a growing interest in early diagnosis of diseases. Among the various diagnostic methods, researchers are actively conducting research on measuring glutamine as an indicator of geriatric diseases by finding that the concentration of glutamine in the cells and blood of patients with serious diseases such as cancer, diabetes, and dementia is significantly changed compared to normal people.
Dr. Seo, Moon-Hyeong of the Natural Product Research Center at the Korea Institute of Science and Technology (KIST), together with Dr. Park, Keunwan of the Natural Product Informatics Research Center, have developed a technology that can quickly and accurately measure glutamine concentrations without complicated measurement processes and expensive analytical equipment through the principle of ‘ligand-induced protein assembly’.
Glutamine is an amino acid in the blood that is used by cells to synthesize proteins or as an energy source, and its rapid fluctuation in certain situations makes it a useful biomarker for the treatment and early diagnosis of disease. For this reason, researchers are actively studying glutamine metabolism in the body to diagnose metabolic and degenerative diseases, including cancer treatment by inhibiting the metabolism of glutamine, which is also a nutrient for cancer cells.
Until now, the measurement of glutamine concentration in the body has relied on expensive specialized analytical equipment such as amino acid analyzers, which cannot measure changes in glutamine concentration in living cells in real time. In the case of relatively low-cost research kits, cumbersome pre-treatment processes such as protein removal in biological samples were required, resulting in long measurement times and low accuracy.
The team developed a sensor protein for measuring glutamine based on the principle of “ligand-induced protein assembly” that can easily measure the concentration of glutamine in the blood. By separating a glutamine binding protein into two artificial proteins and then binding to the sample, and named it Q-SHINE by combining Q, the symbol for glutamine, and SHINE, which means brightly glowing. Experiments showed that the Q-SHINE sensor was highly selective, not responding to amino acids with similar structure such as glutamic acid and D-glutamine. The lowest concentration of glutamine that can be measured is 1 micromolar (µM, one millionth of a molar), which is 20 times lower than the enzymatic assay most commonly used in research kits. In addition, the sensor protein can be easily produced in E. coli, making it possible for a research kit to analyze glutamine concentrations at the same level as analytical instruments worth hundreds of millions of dollars.
The team also used the Q-SHINE sensor to monitor changes in glutamine concentration in the cytoplasm and mitochondria of living cells in real time. In particular, by verifying the difference in glutamine concentration between cancer cells and normal cells, it is expected to speed up the development of anticancer drugs by inhibiting glutamine metabolism.
“The Q-SHINE sensor developed by KIST will enable easy monitoring of glutamine concentration, similar to the self-monitoring of blood glucose by diabetics,” said Dr. Seo, Moon-Hyeong. “If used for glutamine metabolism research, it will greatly contribute to early diagnosis and identification of causes of severe geriatric diseases such as cancer, diabetes, and dementia, as well as development of cancer drugs that regulate glutamine metabolism.”
###
KIST was established in 1966 as the first government-funded research institute in Korea. KIST now strives to solve national and social challenges and secure growth engines through leading and innovative research. For more information, please visit KIST’s website at https://eng.kist.re.kr/
The research, which was supported by the Ministry of Science and ICT (Minister Lee Jong-ho) through the KIST Major Project and the Korea Research Foundation’s Excellent New Research Project, was published in the latest issue of the international journal Sensors and Actuators, B: Chemical (IF=8.4, top 0.8% in JCR).
[ad_2]
National Research Council of Science and Technology
Source link
[ad_1]
Family Dollar voluntarily recalled dozens of over-the-counter drugs, products and medical devices sold at its stores because they had been stored at improper temperatures, according to the Food and Drug Administration late Tuesday.
On the FDA’s website, the regulator said products affected by the recall were stored “outside of labeled temperature requirements by Family Dollar and inadvertently shipped to certain stores on or around June 1, 2023 through September 21, 2023.”
Brands affected by the recall include Procter & Gamble’s
PG,
Crest, Vicks and Pepto Bismol; Colgate
CL,
; Johnson & Johnson Inc.’s
JNJ,
Tylenol and Listerine; and Bayer’s
BAYN,
Aleve, according to a list provided by the FDA.
The items were sold at stores in Alabama, Arkansas, Arizona, California, Colorado, Florida, Georgia, Idaho, Kansas, Louisiana, Mississippi, Montana, North Dakota, Nebraska, New Mexico, Nevada, Oklahoma, Oregon, South Dakota, Texas, Utah, Washington and Wyoming, between June 1 and Oct. 4, the FDA said.
Family Dollar was acquired by Dollar Tree Inc.
DLTR,
in a deal that closed in July 2015.
[ad_2]

[ad_1]
Newswise — DALLAS, Oct. 9, 2023 — Health experts are redefining cardiovascular disease (CVD) risk, prevention and management, according to a new American Heart Association presidential advisory published today in the Association’s flagship journal Circulation.
Various aspects of cardiovascular disease that overlap with kidney disease, Type 2 diabetes and obesity support the new approach. For the first time, the American Heart Association defines the overlap in these conditions as cardiovascular-kidney-metabolic (CKM) syndrome. People who have or are at risk for cardiovascular disease may have CKM syndrome.
The new approach detailed in the presidential advisory includes:
According to the American Heart Association’s 2023 Statistical Update, 1 in 3 U.S. adults have three or more risk factors that contribute to cardiovascular disease, metabolic disorders and/or kidney disease. CKM affects nearly every major organ in the body, including the heart, brain, kidney and liver. However, the biggest impact is on the cardiovascular system, affecting blood vessels and heart muscle function, the rate of fatty buildup in arteries, electrical impulses in the heart and more.
“The advisory addresses the connections among these conditions with a particular focus on identifying people at early stages of CKM syndrome,” said Chiadi E. Ndumele, M.D., Ph.D., M.H.S., FAHA, writing committee chair and an associate professor of medicine and director of obesity and cardiometabolic research in the division of cardiology at Johns Hopkins University in Baltimore. “Screening for kidney and metabolic disease will help us start protective therapies earlier to most effectively prevent heart disease and best manage existing heart disease.”
CKM syndrome is a consequence of the historically high prevalence of obesity and Type 2 diabetes in both adults and youth, according to the advisory. Type 2 diabetes and obesity are metabolic conditions — the “M” in CKM — that are also risk factors for cardiovascular disease. Moreover, the most common cause of death for people with Type 2 diabetes and chronic kidney disease is cardiovascular disease.
“We now have several therapies that prevent both worsening kidney disease and heart disease,” Ndumele said. “The advisory provides guidance for health care professionals about how and when to use those therapies, and for the medical community and general public about the best ways to prevent and manage CKM syndrome.”
With multiple conditions to manage, Ndumele noted fragmented care is a concern in treating patients with CKM syndrome, particularly for those with barriers to care. “The advisory suggests ways that professionals from different specialties can better work together as part of one unified team to treat the whole patient.” Additionally, the advisory emphasizes the importance of systematically screening for and addressing social factors that act as determinants, or drivers, of health, such as nutrition insecurity and opportunities for exercise, as key aspects of optimal CKM syndrome care.”
A companion article published with the presidential advisory, a new American Heart Association scientific statement, “A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome,”, documents the evidence for the writing committee’s proposed approach. The scientific statement brings together evidence from current guidelines and large research studies and describes where gaps remain in knowledge needed to further improve CKM health.
CKM screening, stages and treatment
CKM-related screening is intended to detect cardiovascular, metabolic and kidney health changes early; identify social and structural barriers to care; and prevent progression to the next stage of CKM syndrome.
The advisory addresses care for adults. However, studies suggest CKM syndrome is progressive and begins early in life. Therefore, the advisory aligns with the American Academy of Pediatrics’ recommendations for children and youth to have annual assessments of weight, blood pressure, and mental and behavioral health, starting at age 3.
Stage 0 – No CKM risk factors. The goal at this stage is preventing CKM syndrome by achieving and maintaining ideal health based on the American Heart Association’s Life’s Essential 8 recommendations. The recommendations include healthy eating, physical activity and sleep habits; avoiding nicotine; and maintaining optimal weight, blood pressure, blood sugar and cholesterol levels. The advisory suggests screening adults in Stage 0 every three to five years to assess blood pressure, triglycerides, HDL (good) cholesterol and blood sugar.
Preventing unhealthy weight gain is important for CKM syndrome prevention because of the connection of obesity to Type 2 diabetes, high blood pressure and high triglycerides. At all stages, the advisory proposes yearly measurement of waist circumference and body mass index. Healthy lifestyle behaviors are also encouraged at every stage.
Stage 1 – Excess body fat and/or an unhealthy distribution of body fat, such as abdominal obesity, and/or impaired glucose tolerance or prediabetes. Support for healthy lifestyle changes (healthy eating and regular physical activity) and a goal of at least 5% weight loss in people with Stage 1 are suggested, with treatment for glucose intolerance if needed. Screening every two to three years is advised to assess blood pressure, triglycerides, cholesterol and blood sugar.
Stage 2 – Metabolic risk factors and kidney disease. Stage 2 includes people with Type 2 diabetes, high blood pressure, high triglycerides or kidney disease, and indicates a higher risk for worsening kidney disease and heart disease. The goal of care at this stage is to address risk factors to prevent progression to cardiovascular disease and kidney failure. Treatment may include medications to control blood pressure, blood sugar and cholesterol. In those with chronic kidney disease and in some people with Type 2 diabetes, SGLT2 inhibitors are advised to protect kidney function and reduce the risk of heart failure. SGLT2 inhibitors are a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with Type 2 diabetes. Glucagon-like peptide 1 (GLP-1) receptor agonists are also suggested for consideration in people with Type 2 diabetes to help reduce high glucose, facilitate weight loss and reduce risk for CVD. Other therapies to prevent worsening kidney function are also advised. Screening suggestions for Stage 2 CKM syndrome align with AHA/ACC guidelines, which include yearly assessment of blood pressure, triglycerides, cholesterol, blood sugar and kidney function.
For those with increased risk of kidney failure based on kidney function assessments, more frequent kidney screening is recommended.
Stage 3 – Early cardiovascular disease without symptoms in people with metabolic risk factors or kidney disease or those at high predicted risk for cardiovascular disease. The goal of care in Stage 3 is to intensify efforts to prevent people who are at high risk of progressing to symptomatic cardiovascular disease and kidney failure. This may involve increasing or changing medications, and additional focus on lifestyle changes. The writing committee advises coronary artery calcium (CAC) measurement in some adults to assess narrowing of the arteries when treatment decisions are unclear. CAC screening is used to guide decisions about cholesterol-lowering statin therapy. Test results indicating asymptomatic heart failure should lead to intensified therapy to prevent heart failure symptoms.
The advisory also describes CKM syndrome regression, an important concept and public health message in which people making healthy lifestyle changes and achieving weight loss may regress to lower CKM syndrome stages and a better state of health. The best opportunity for patients to experience regression is in Stages 1, 2 and 3. Some may see improvements in glucose control, cholesterol and blood pressure levels, weight, kidney function and types of heart dysfunction.
Stage 4 – Symptomatic cardiovascular disease in people with excess body fat, metabolic risk factors or kidney disease. Stage 4 CKM syndrome is divided into two subcategories: (4a) for those without kidney failure or (4b) for those with it. In this stage, people may have already had a heart attack or stroke or may already have heart failure. They also may have additional cardiovascular conditions such as peripheral artery disease or atrial fibrillation. The goal of care is individualized treatment for cardiovascular disease with consideration for CKM syndrome conditions.
Predicting Risk
A critical step in assessing risk and managing CKM syndrome is updating the risk prediction algorithm to help health care professionals predict cardiovascular disease in a way that includes CKM components: cardiovascular disease, chronic kidney disease and metabolic disorders.
The Pooled Cohort Equation, the current risk calculator for atherosclerotic cardiovascular disease, established in 2013, estimates the risk of a heart attack or stroke in the next 10 years for people ages 40-75. It includes health and demographic factors about a person and is used to guide lifestyle recommendations and treatment decisions for people at risk for cardiovascular disease. The risk factors are age, sex and race (as white, Black and other); cholesterol levels; and systolic blood pressure. The equation also includes yes/no responses to whether a person is receiving treatment for high blood pressure Type 2 diabetes, or smokes cigarettes.
The advisory proposes updating the risk calculator to include measures of kidney function, Type 2 diabetes control (using blood test results instead of a yes/no response) and social determinants of health for a more comprehensive risk estimate. Kidney function assessments include a measure of how well the kidneys filter waste from the blood and urine albumin levels, a measure of how well the kidneys reabsorb protein. Individual health measures in addition to demographic information will allow the calculator to produce an individual’s total CVD risk estimate.
The writing group recommends the risk calculator updates be expanded to assess risk in people as young as age 30 and to calculate both 10- and 30-year CVD risk. More comprehensive CVD risk assessment at younger ages will allow for earlier preventive strategies to mitigate progression to advanced stages of CKM syndrome. In the long term, this will help to reduce gaps in treatment and health equity and improve outcomes.
Calls to Action
The advisory calls for systemic changes to optimize CKM health.
“There is a need for fundamental changes in how we educate health care professionals and the public, how we organize care and how we reimburse care related to CKM syndrome,” Ndumele said. “Key partnerships among stakeholders are needed to improve access to therapies, to support new care models and to make it easier for people from diverse communities and circumstances to live healthier lifestyles and to achieve ideal cardiovascular health.”
Investing in research is important for advancing CKM care. Key research gaps include:
Co-authors and their disclosures are listed in the manuscript.
This presidential advisory was prepared by the volunteer writing group on behalf of the American Heart Association. Presidential advisories and scientific statements promote greater awareness about cardiovascular diseases and stroke and help facilitate informed health care decisions. They outline what is known about a topic and what areas need additional research. While scientific statements and advisories inform the development of guidelines, they do not make treatment recommendations. American Heart Association guidelines provide official clinical practice recommendations.
The Association receives funding primarily from individuals. Foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers, and the Association’s overall financial information are available here.
Additional Resources:
[ad_2]
American Heart Association (AHA)
Source link

[ad_1]
Newswise — October 9, 2023 – Black patients report more difficulties relating to their orthopaedic surgeon and are more likely to perceive bias from their surgeon, as compared with White patients, reports a study in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.
“Black patients were six times more likely to report difficulty relating to their surgeon and 14 times more likely to report perceived racial bias compared with their White counterparts,” according to the survey study by Marsalis Brown, MD, of University Hospitals – Cleveland Medical Center, and colleagues. The research also shows race- and gender-related differences in patient preferences for orthopaedic surgeons with specific characteristics.
Survey shows racial differences in patient experiences
The study evaluated patients’ experiences, perceptions, and preferences related to diversity in orthopaedic surgery. The survey included 349 patients seen at orthopaedic clinics within the authors’ health system. About 80% of respondents were White and 18% were Black; only about three percent were Hispanic.
The results showed differences in patient experiences between racial groups. Black patients were more likely to report difficulties relating to their orthopaedic surgeon, as compared with White patients: 11.48% versus 2.29%. Black patients were also much more likely to perceive racial bias from their surgeon: 5.17% versus 0.37%.
Patients perceived low levels of diversity within orthopaedic surgery (average rating of 2.5 out of 10) with only a small difference between Black and White patients (2.10 versus 2.57). Black patients ranked race as a more important factor to consider when selecting a surgeon: average rating 3.49 compared with 1.45 for White patients.
Women report more difficulty relating to their orthopaedic surgeon
Women were about five times more likely to report difficulty relating to their surgeon. Although male and female patients had similar perceptions of diversity in orthopaedic surgery, women placed more importance on their surgeon’s gender.
The study also found some differences according to patient income and education, with more-educated patients perceiving lower diversity among surgeons. That perception is consistent with the slow rate of change in representation of racial and ethnic minorities and women in orthopaedic surgery, which lags behind other surgical specialties.
The findings are especially important in light of recent studies, which have shown that diversity leads to higher patient satisfaction, greater adherence to recommended treatment, and improvement in the patient-physician relationship. “Despite the ongoing education reforms to encourage increased diversity during trainee selection, the impact of such efforts is yet to manifest as changes in patient perceptions in current practice settings,” Dr. Brown and coauthors write. They discuss the critical need for reforms early in medical education, including early exposure to orthopaedic surgery, improving access to mentors, and steps to improve retention through each educational level.
Read Article [ Patient Preferences and Perceptions of Provider Diversity in Orthopaedic Surgery ]
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
###
About The Journal of Bone & Joint Surgery
The Journal of Bone & Joint Surgery (JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field. A core journal and essential reading for general as well as specialist orthopaedic surgeons worldwide, The Journal publishes evidence-based research to enhance the quality of care for orthopaedic patients. Standards of excellence and high quality are maintained in everything we do, from the science of the content published to the customer service we provide. JBJS is an independent, non-profit journal.
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in professional information, software solutions, and services for the healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2022 annual revenues of €5.5 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,900 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Twitter, Facebook, and YouTube.
[ad_2]
Wolters Kluwer Health: Lippincott
Source link